Compare TKNO & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | WHF |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 164.5M |
| IPO Year | 2021 | N/A |
| Metric | TKNO | WHF |
|---|---|---|
| Price | $3.21 | $7.57 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | ★ 104.0K | 84.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.53% |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | $15.35 |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $6.07 |
| 52 Week High | $7.48 | $9.68 |
| Indicator | TKNO | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 55.50 |
| Support Level | $3.01 | $6.80 |
| Resistance Level | $3.25 | $7.62 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 77.65 | 34.29 |
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.